Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2239577rdf:typepubmed:Citationlld:pubmed
pubmed-article:2239577lifeskim:mentionsumls-concept:C0008972lld:lifeskim
pubmed-article:2239577lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2239577lifeskim:mentionsumls-concept:C0033581lld:lifeskim
pubmed-article:2239577lifeskim:mentionsumls-concept:C0085696lld:lifeskim
pubmed-article:2239577lifeskim:mentionsumls-concept:C0039082lld:lifeskim
pubmed-article:2239577lifeskim:mentionsumls-concept:C0752221lld:lifeskim
pubmed-article:2239577lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:2239577pubmed:issue7lld:pubmed
pubmed-article:2239577pubmed:dateCreated1990-12-7lld:pubmed
pubmed-article:2239577pubmed:abstractTextKampo treatment was attempted in cases of chronic nonbacterial prostatitis and prostatitis-like syndrome which was intractable or recurred when treated with western medicine. The clinical effects of Kampo treatment were excellent in 21.3% with an efficacy rate of 67.2% for the cases with chronic non-bacterial prostatitis, and excellent in 19.5% with an efficacy rate of 52.4% in the cases with prostatitis-like syndrome. When the clinical effects were compared with those of western therapy performed in the cases which had recurrence, Kampo treatment showed more excellent effects (p less than 0.1) for both types of disease, and the treatment with Chinese medicine was suggested useful. In a comparison of the effects between the cases given only Kampo treatment and those given both Kampo treatment and western treatment using anti-inflammatory agents, no difference was seen in the cases with the prostatitis-like syndrome, but in the cases with chronic non-bacterial prostatitis, the effects were better in the concomitant treatment group than in the group given only Kampo treatment (p less than 0.1). The response to the Kampo treatment differed depending on the type of disease. Among the antibacterial agents used concomitantly in the cases of chronic non-bacterial prostatitis, new-quinolones showed better results than ST compounds or tetracyclines, but no statistically significant differences were seen among the drugs. Of the Kampo drugs used, Keisibukuryogan and Simotuto showed high clinical usefulness in both types of disease and there was no statistically significant difference among the other drugs. The incidence rate of side effects (Goji) due to Kampo treatment was 6.3% and was higher in patients administered Keisibukuryogan.lld:pubmed
pubmed-article:2239577pubmed:languagejpnlld:pubmed
pubmed-article:2239577pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2239577pubmed:citationSubsetIMlld:pubmed
pubmed-article:2239577pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2239577pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2239577pubmed:statusMEDLINElld:pubmed
pubmed-article:2239577pubmed:monthJullld:pubmed
pubmed-article:2239577pubmed:issn0018-1994lld:pubmed
pubmed-article:2239577pubmed:authorpubmed-author:IkeuchiTTlld:pubmed
pubmed-article:2239577pubmed:issnTypePrintlld:pubmed
pubmed-article:2239577pubmed:volume36lld:pubmed
pubmed-article:2239577pubmed:ownerNLMlld:pubmed
pubmed-article:2239577pubmed:authorsCompleteYlld:pubmed
pubmed-article:2239577pubmed:pagination801-6lld:pubmed
pubmed-article:2239577pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:meshHeadingpubmed-meshheading:2239577-...lld:pubmed
pubmed-article:2239577pubmed:year1990lld:pubmed
pubmed-article:2239577pubmed:articleTitle[Clinical studies on chronic prostatitis and prostatitis-like syndrome (4). The kampo treatment for intractable prostatitis].lld:pubmed
pubmed-article:2239577pubmed:affiliationDepartment of Urology, Fujigaoka Hospital, School of Medicine, Showa University.lld:pubmed
pubmed-article:2239577pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2239577pubmed:publicationTypeEnglish Abstractlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2239577lld:pubmed